News
From innovation in manufacturing to more-flexible regulation and better communication with payers, much needs to happen to ...
Sarepta and Capricor learned of key regulatory decisions from the media and investors, and Duchenne muscular dystrophy ...
Parents of boys with Duchenne muscular dystrophy weigh in on drug innovation and medical regulation.
Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy ...
The U.S. Food and Drug Administration's (FDA) top vaccine official is stepping down after just three months in a role that ...
But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than ...
A biopharmaceutical research company with ties in Andover has laid off a third of its workforce as one of the leaders in gene therapy goes through a “strategic ...
At the 2025 Alzheimer’s Association International Conference, one of the bigger splashes was made by an experimental cardiovascular drug. Newamsterdam Pharma Co. NV presented data showing that its ...
The Food and Drug Administration’s polarizing vaccine chief is leaving the agency after a brief tenure that drew the ire of ...
5d
Amazon S3 on MSNThe story of Sarepta's Duchenne gene therapyThe last couple of weeks has been particularly distressing for Duchenne muscular dystrophy patients and their families. The ...
In the latest episode of STATus Report, Alex Hogan breaks down the confusing, heartbreaking saga of Sarepta and its gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results